Cognitive Rehabilitation in Post-COVID-19 Syndrome

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Nov 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a program called CO-OP, which stands for Cognitive Orientation to daily Occupational Performance. The goal is to see if this program can help people who have cognitive difficulties after recovering from COVID-19, known as Post-COVID-19 Syndrome (PCS). The researchers want to find out if CO-OP can improve how well participants can perform everyday activities, their thinking abilities, and their overall quality of life. They believe that those who participate in CO-OP will show more improvement than those who do not receive this treatment.

To be eligible for the trial, participants should be ages 18 to 75 and have been experiencing cognitive problems for at least six weeks after a COVID-19 infection. They also need to have specific goals related to daily activities and be able to understand and communicate in English. However, individuals with severe brain or psychiatric conditions, symptoms of dementia, untreated sleep apnea, or certain other health issues will not be able to participate. If someone joins this study, they can expect to engage in remote sessions to work on their cognitive skills and improve their daily functioning. The trial is currently recruiting participants, and it promises to provide valuable insights into helping those affected by cognitive issues after COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • self-reported cognitive symptoms persisting for at least 6 weeks following COVID-19 infection (Cognitive Failures Questionnaire (CFQ) score \>43)
• • self-identified activity performance goals per the Canadian Occupational Performance Measure (COPM)
• • documented prior diagnosis of COVID-19
• • read, write, and speak English fluently
• • ability to provide valid informed electronic consent
• Exclusion Criteria:
• • diagnosis of severe neurological or psychiatric condition(s)
• • dementia symptoms as indicated by a score of \<23 on the Montreal Cognitive Assessment (MoCA)
• • untreated sleep apnea (≥5 on the STOPBANG)
• • prior cancer treatment
• • severe depressive symptoms (\>21 on the Patient Health Questionnaire-9)